Background Gestational diabetes mellitus (GDM) is an increasingly prevalent disorder, associated with low blood vitamin D level.
Introduction
Gestational diabetes mellitus (GDM) is hyperglycaemia that is first recognised at any stage of pregnancy, in which the blood glucose levels are slightly elevated. It was estimated that 13.8% of women having live births had GDM in 2015 globally. Women with GDM are at greater risk of adverse pregnancy outcomes, including high blood pressure and fetal macrosomia. 1 Hence, it is of significant importance to explore the prevention and treatment of GDM.
Numerous researchers have explored the possible risk factors of GDM. Vitamin D is one of the highlights in this field, because low blood vitamin D level is a notable public health issue and intake of vitamin D can be practically modified. It is estimated that 7-98% of pregnant women suffer from vitamin D deficiency. 2, 3 Various study designs focused on the relationship between vitamin D and GDM. Some researchers investigated mechanisms for the effect of vitamin D on GDM, and implied that vitamin D could regulate hepatic metabolism, the function and development of pancreatic islets, blood calcium level, oxidative stress, the immune system and inflammation to mediate the onset of GDM. [4] [5] [6] [7] Meanwhile, population-based studies were implemented, but the results were inconsistent. Several prospective observational studies concluded that a low blood vitamin D level in the first and second trimesters could increase the risk of GDM, 8, 9 whereas others failed to find such associations. [10] [11] [12] [13] Besides, most randomised controlled trials (RCTs) supported the idea that supplementing with vitamin D during pregnancy could reduce the level of blood sugar and insulin, [14] [15] [16] whereas the results of other related biomarkers were far from consistent and valid. [14] [15] [16] [17] [18] [19] [20] A valid conclusion is unlikely to be reached by simply enumerating the results above. Hence, several meta-analyses have been conducted and found that a low blood vitamin D level might increase the risk of GDM. [21] [22] [23] But these studies did not exhaust the databases to include as many studies and GDM-related indices as possible and include RCTs. Therefore, a systematic review and meta-analysis with more studies and related parameters was conducted to evaluate the relationship between vitamin D and GDM comprehensively.
Methods
Information sources and search strategy MEDLINE, EMBASE and Cochrane Library were searched for studies describing the association between vitamin D and GDM up to 15 April 2017, and the China Biology Medicine (CBM) disc was searched up to 16 May 2017. In addition, the reference lists of the included studies were searched to identify additional relevant publications. Five themes of Medical Subject Heading terms and related exploded versions were focused on, including vitamin D, glucose, insulin, glycosylated haemoglobin and GDM. The detailed searching strategies are shown in the Supplementary material (Appendix S1).
Eligibility criteria
Only the data free of Hawthorne effect and related to GDM were included. Specifically, vitamin D should be supplemented within RCTs, and the blood used for analysing vitamin D concentration should be collected before or during oral glucose tolerance test or blood draw for other biomarker analyses in observational studies. Under this circumstance, participants would not adopt healthier behaviours because they would be unaware of their GDM condition. Besides, the core outcome sets including GDM occurrences, fasting plasma glucose (FPG), fasting insulin (FINS), homeostasis model of assessment for insulin resistance index (HOMA-IR), homeostasis model of assessment for b cell function (HOMA-B) and glycosylated haemoglobin (HbA1c) need to be reported in the original studies. Other biomarkers related to GDM including C-reactive protein (CRP), glutathione (GSH), total antioxidant capacity (TAC), high-density lipoprotein (HDL), low-density lipoprotein (LDL), triacylglycerol (TAG) and total cholesterol (TC) should also be included.
Studies were considered to be excluded if they were: (i) duplicate publications, (ii) non-original studies, (iii) nonhuman studies, (iv) studies irrelevant to pregnancies' blood vitamin D level, (v) studies with unreasonable and nonamendable data or statistical methods, or (vi) inaccessible data or full texts.
Eligible conference papers were included in this study, as it was not obvious that unpublished articles were of poor quality, and leaving out eligible articles could result in lower powerful tests and greater publication bias. 24 
Information extraction and quality evaluation
Two investigators (YZ and HX) extracted data and evaluated the quality of literature independently. Divergences were resolved by consensus, or by consulting with the third investigator (GC).
For observational studies, study characteristics, blood level of 25-hydroxyvitamin D (25OHD, which is formed from vitamin D in liver and is stable enough to be measured as a biomarker 25 ) and disease outcomes were extracted with a piloted chart (see Table S1 ). For RCTs, study characteristics, intervention methods and outcomes of biomarkers related to GDM were extracted with a piloted chart (see Table S2 ). If the information was unavailable from a published report, the authors were contacted to obtain access to the data.
Low blood vitamin D level could be classified into vitamin D deficiency and vitamin D insufficiency. However, the cut offs used to differentiate vitamin D status are not reached in agreement. Some researchers used 50 nmol/l and 75 nmol/l to differentiate vitamin D deficiency, vitamin D insufficiency and vitamin D sufficiency, 10 whereas others used 25 nmol/l and 50 nmol/l. 26 For the quality of observational studies, NewcastleOttawa Scale focusing on the selection of the study groups (four scores), the comparability of the groups (two scores), and the ascertainment of either the exposure or outcome for case-control or cohort studies (three scores) was used to score. Studies with a score of no less than seven were regarded as high quality. 27 The quality of RCTs was evaluated according to the Cochrane Handbook, which focused on the biases generated from random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data and other sources. 28 If five or more items are regarded as low risk, the study quality will be graded as A. If four items are regarded as low risk, the study quality will be graded as B. Otherwise, the study quality will be graded as C.
Data synthesis and statistical analyses
COMPREHENSIVE META ANALYSIS software (Version 2.2.064) was used for all statistical analyses. Since the time, location and population of studies were varied, randomeffects models were used to pool the data and conduct meta-regression. The formats of original data and conversion formulae for effect sizes are listed in the Supplementary material (Table S3 ). Forest plots were depicted to visually assess the effect sizes and 95% CIs across the studies.
Heterogeneity across studies was assessed by the Q statistic (significance level of P < 0.10) and the I 2 statistic (from 0 to 100% with lower values representing less heterogeneity). When P < 0.10 or I 2 > 50%, we performed stratified analysis and meta-regression to explore the sources of heterogeneity. 24 The categorical variables and continuous variables in the Supplementary material (Tables S1 and S2) were used for stratified analyses and meta-regression. Interpretation of the results was not performed in the subgroups, when the number of the studies was < 10% of the total. When the heterogeneity in subgroups was insignificant or the P-value of the meta-regression's slope was < 0.05, we considered the corresponding variables as the sources of heterogeneity.
For sensitivity analysis, one study was omitted at each time to test the robustness of the results and the influence of this individual study on the pooled result. 24 If the direction and statistical significance of the effects remained the same, we concluded that the individual study did not influence the results dramatically.
Three methods were used to evaluate the publication bias. 24 First, funnel plots were depicted to judge if there were publication biases. The publication bias was suspected only when the image was asymmetrical. Second, classic failsafe N statistic was used to compute the number of studies that would be required to nullify the effect, which was suitable for the statistically significant results only. A relatively small number suggested that a few negative results that could be unpublished due to publication bias to be included could change the existing results. Third, Duval and Tweedie's trim and fill was used to determine where the missing studies were supposed to be located to make the funnel plot symmetrical, to add them to the analysis, and then to re-compute the combined effect.
Results

Literature search
Based on the searching strategy, 1386 unique citations were identified. Under the inspection of the titles and abstracts according to the aforementioned criteria, 1022 articles were excluded. Through manual inspections, 87 observational studies (including 55 859 participants) and 25 RCTs (including 2445 participants) were included (see Appendix S2). Notably, one paper reported an observational study and an RCT simultaneously. The detailed procedure is shown in the Supplementary material ( Figure S1 ) as are the characteristics of the eligible studies (Table S1 and S2).
Blood vitamin D concentration during pregnancy and risk of GDM
The present meta-analysis including 38 studies showed that gravidas with low blood vitamin D level had 85.0% higher risk of GDM than gravidas with regular vitamin D level (OR 1.850, 95% CI 1.471-2.328; Figure 1 ). As I 2 was 56.53%, stratified analysis and meta-regression were performed. And I 2 was < 50% when analysis was stratified according to the categorisation of vitamin D status and the economic development level of countries, whereas the pooled odds ratio (95% CI) for developed countries was 1.211 (0.928-1.579, see Table S4 ), which was not statistically significant, and meta-regression implied that the median study time might be the source of heterogeneity (see Table S5 ).
The present meta-analysis including 58 studies indicated that the blood 25OHD concentration of gravidas with GDM was lower than that of healthy gravidas [standard mean difference (SMD) À0.567, P < 0.001; Figure 2 ). Since I 2 was 50.92%, stratified analysis and meta-regression were conducted. I 2 was < 50% when analysis was stratified according to conference paper or not and the economic development level of countries. Likewise, the P-value for developed countries was no longer statistically significant (see Table S4 ). Meta-regression implied that the latitude of the study location and the proportion of gravidas with regular vitamin D level might be the sources of heterogeneity (see Table S5 ). Hence, the blood 25OHD concentration of gravidas with GDM might be lower than that of healthy gravidas, especially in developing countries, whereas the actual situation might be distinct in different regions or populations.
Omitting one study at each time, all the directions and statistical significances of the effects remained the same. The studies in the funnel plots were distributed symmetrically regarding the combined effect sizes, and the fail-safe values of N were 10 356 and 842, respectively. This meant that 10 356 and 842 null studies needed to be included in order for the combined two-tailed P-value to exceed 0.050, which was difficult to realise. Therefore, the pooled data were robust and invulnerable to publication bias. Each solid square represents the odds ratio of the individual original study, with the location of the square representing both the direction and magnitude of the effect. The odds ratio for each study is bounded by a confidence interval (CI). The summary effect is represented by a diamond, with the location of the diamond representing the effect size while its width reflects the precision of the estimate. The odds ratio of low blood vitamin D level with GDM is 1.850 (95% CI 1.471-2.328).
The relationships between blood vitamin D concentration during pregnancy and biomarkers related to GDM
The present meta-analysis found that the blood concentration of 25OHD was inversely correlated to HbA1c, FINS level, FPG level and HOMA-IR. The correlation coefficients (95% CI) were À0.066 (À0.262 to 0.135), À0.487 (À0.829 to 0.120), À0.100 (À0.166 to À0.033), and À0.351 (À0.594 to À0.050), respectively (see Figures S2-S5) . The latter two correlations were statistically significant. Additionally, the corresponding I 2 statistics were 0, 28.76%, 0 and 10.67%, suggesting that exploring the sources of heterogeneity was unessential.
The studies on the relationship between blood 25OHD concentration and FINS level in the funnel plot were distributed asymmetrically regarding the combined effect size. Duval and Tweedie's trim and fill suggested that two studies were missing, which might result from publication bias. Imputing these two studies could make the funnel plot symmetric, and the point estimate (95% CI) changed to À0.613 (À0.863 to À0.121), which was statistically significant. The studies on the relationship between blood 25OHD concentration and HOMA-IR in the funnel plot were also distributed asymmetrically. Trim and fill suggested that five studies were missing and the imputed point estimate (95% CI) was À0.454 (À0.620 to À0.250), which was still statistically significant. Other funnel plots were symmetrical. The fail-safe N for the correlations between maternal blood 25OHD level and FINS level, FPG level and HOMA-IR were 1 516, 245 and 2615, respectively. When we omitted one study at each time, all the directions and statistical significances of the effects remained the same. Therefore, the FPG level and HOMA-IR might be inversely correlated to blood 25OHD level during pregnancy, and the inverse correlation between the FINS level and blood 25OHD level during pregnancy might be concealed by the publication bias.
The effect of vitamin D supplementation during pregnancy on biomarkers related to GDM
The present meta-analysis showed that vitamin D supplementation during pregnancy could elevate the blood 25OHD (SMD = 1.768, P < 0.001, I 2 = 38.56%), GSH (SMD = 0.828, P = 0.003, We further explored the sources of heterogeneity. For the effect of vitamin D supplementation on FINS level, I 2 statistics for all stratified analyses were > 50% (see Table S4 ), whereas the slopes were statistically significant when we used average intervention doses per day and intervention duration as covariates to conduct meta-regression (see Table S5 ). For the effect on TAC, we found that I 2 was < 50% when analysis was stratified according to the health condition of the participants (divided into gravidas with or without GDM), and vitamin D supplementation might enhance TAC in gravidas without GDM (SMD = 2.245, P = 0.03; see Table S4 ). Moreover, metaregression implied that intervention duration might be one of the sources of heterogeneity (see Table S5 ).
Omitting one study at each time, the statistical significances of the effects of vitamin D supplementation during pregnancy on GSH level, CRP level, TC level, HDL level and GDM prevention changed ( Table 1) .
The analyses of publication biases are shown in Table 2 . Above all, the results for the effect of vitamin D supplementation on blood 25OHD concentration, FINS level, FPG level and HOMA-IR were robust and barely influenced by publication biases. Other results were either not robust or vulnerable to the publication biases.
Discussion
Main findings
This systematic review intended to straighten out the current evidence regarding the preventive and therapeutic Figure 2 . Standard mean difference (SMD) between gravidas with and without gestational diabetes mellitus (GDM). The forest plot shows SMD between gravidas with and without GDM. Data are from 32 191 gravidas. Each solid square represents the SMD of the individual original study, with the location of the square representing both the direction and magnitude of the effect. The SMD for each study is bounded by a confidence interval (CI). The summary effect is represented by a diamond, with the location of the diamond representing the effect size while its width reflects the precision of the estimate. The SMD between gravidas with and without GDM is À0.576 (95% CI À0.724 to À0.428).
effects of vitamin D on GDM. The following conclusions were reached after analysing the data from 87 observational studies and 25 RCTs. First, low blood vitamin D level could increase the risk of GDM. Meanwhile, the blood vitamin D concentration in gravidas with GDM was lower than in gravidas without GDM. However, whether these results applied to developed countries or not remained unclear. Second, the blood vitamin D concentration in gravidas was inversely correlated with FPG level and HOMA-IR, and was inversely correlated with FINS level after adjusting the publication bias. Third, supplementing vitamin D during pregnancy could effectively change the blood concentrations of 25OHD, FINS, FPG, GSH, CRP, TC, LDL, HDL and HOMA-IR, but the results on the level of GSH, CRP, TC, LDL and HDL were far from robust and were susceptible to publication biases.
Strengths and limitations
The differences in concrete results between this systematic review and other related studies might result from the following reasons. First, only data free of the Hawthorne effect were included in this meta-analysis, which meant that the participants were unaware of their conditions and consequently unmotivated to adopt healthier behaviours to prevent or treat GDM and change their vitamin D status. This is essential for elucidating causation. Other studies had either laxer or stricter inclusion criteria for study designs. For instance, Lu et al. included all observational studies evaluating the association between vitamin D status and risk of gestational diabetes, which could be biased by Hawthorne effect, 23 whereas Poel et al. only pooled the data from prospective observational studies, which could omit other high-quality studies with data free of Hawthorne effect. 21 Second, to increase the power of test and the robustness of the results, 87 observational studies and 25 RCTs, which included 55 859 and 2445 participants, respectively, were analysed in this meta-analysis, whereas the maximum number of studies included in the previous meta-analyses was 20. Third, more diverse biomarkers and indices related to GDM were analysed, and the data from RCTs were pooled for the first time, which could help to implicate causality more comprehensively. Fourth, the methods of meta-analysis were exhausted and the results were carefully interpreted to reach a reliable and reasonable conclusion. Heterogeneity test along with stratified analysis and meta-regression, sensitivity examination, and analysis of publication bias could support our Symmetric --*The statistical significance of the result was changed after imputing the missing studies according to trim and fill. comprehensive and well-informed understanding of the results. Specifically, considering the publication bias and sensitivity examination, we identified the unreliable results that required further evaluation.
However, this study had several limitations. On the one hand, publications on RCTs were limited, so the effects of vitamin D supplementation on inflammation, oxidative stress and blood lipid were hard to validate. On the other hand, most of the data from conference papers were inaccessible, so there was the potential to include more studies and participants. Most conference papers only report the pooled odds ratio and the difference in the blood vitamin D level between gravidas with and without GDM, however, the fail-safe N values for these two results were large enough to neglect the influence of publication bias. Considering these limitations and the modest association strength, the effectiveness of vitamin D supplementation during pregnancy needs to be evaluated further, and vitamin D supplementation must be accompanied by other lifestyle interventions to facilitate GDM prevention and treatment.
Interpretation
The results of this systematic review supported the aforementioned mechanisms for the effect of vitamin D on GDM to some extent. [4] [5] [6] [7] Specifically, the changes of FPG level, FINS level and HOMA-IR after supplementing vitamin D, and the inverse correlation between blood vitamin D concentration and these indices indicated that blood vitamin D level might result from the change of function and development of pancreatic islets. 29 Besides, the effect of vitamin D supplementation on the blood lipid concentration might result from the amelioration of hepatic metabolism, because the liver is the main organ for lipogenesis. The glucose will be converted to fat when the intake exceeds the storage and oxidation capacities, whereas plentiful hepatic lipid may induce inflammation and hepatic insulin resistance. 30 Moreover, CRP was an acute-phase protein of hepatic origin reflecting the inflammation. In vitro experiments indicated that vitamin D could directly enhance the development of T helper 2 cells from naive CD4 + T cells. 31 T helper 2 cells secreted interleukin-6, a major proinflammatory cytokine, followed by the increase of CRP. In animal models, interleukin-6 could induce gluconeogenesis, subsequent hyperglycaemia and hyperinsulinaemia. 7, 32 In addition, GSSG/2GSH was one of the biological redox couples in cells to maintain redox homeostasis. The imbalance of antioxidant and pro-oxidant could damage insulin function and enhance the inflammation, which could result in insulin resistance. 33 The results were also consistent with previous meta-analyses. Three meta-analyses on observational studies found that the gravidas with vitamin D deficiency or insufficiency were more likely to suffer from GDM, and the blood vitamin D concentration was lower in gravidas with GDM compared with those without GDM. [21] [22] [23] In addition, the published meta-analyses showed that the economic development level of the country, the study design, the method of vitamin D analysis, the sample size, the quality of the study, and whether the confounding was adjusted or not could influence the combined estimate. [21] [22] [23] Although this study identified the economic development level of the country, the latitude of the study location, the proportion of gravidas with regular vitamin D level, the median study time, the average intervention doses per day and the intervention duration as covariates interfering with the relationship between vitamin D and GDM. These minor inconsistencies in the sources of heterogeneity between these studies could be explained reasonably. On the one hand, the present meta-analysis included more studies and participants than before, so the heterogeneity between studies included in this analysis was reasonably different from previous analyses. On the other hand, considering the power of the test, the subgroup analyses and meta-regressions with limited studies were not interpreted in this systematic review, whereas other studies analysed all the results equally.
Conclusions
In conclusion, low blood vitamin D level during pregnancy could be related to the onset of GDM, especially in developing countries. Also, biomarkers and indices related to blood sugar, insulin, inflammation, oxidative stress and blood lipid might be correlated with blood vitamin D concentration, whereas more related studies need to be conducted to reach a more robust and unbiased conclusion. Hence, the safety and effectiveness of vitamin D supplementation during pregnancy in different regions and populations demand further evaluation -then the related beneficial policies and recommendations will be devised.
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